Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene

17 Sept 2021

Abstract excerpt

Introduction PARP inhibition may enhance antitumor responses in BAP1 -associated mesothelioma by inducing synthetic lethality. Methods A single-center, nonrandomized, phase 2 trial was conducted, in which patients with refractory mesothelioma were given olaparib 300 mg twice daily in a 21-day cycle until disease progression or intolerable toxicity. The primary objective was to determine the objective response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Nuclear Structure and Function
Share to Occupational and environmental lung diseases
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34661178
DOI: 10.1016/j.jtocrr.2021.100231

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 GenePMID 34661178Read ↗

Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival.Semantic proximity Read ↗

Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural MesotheliomaSemantic proximity Read ↗

BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic PerspectivesSemantic proximity Read ↗

Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase InhibitionSemantic proximity Read ↗

Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 MutationsSemantic proximity Read ↗

The spectrum of tumors harboring BAP1 gene alterations.Semantic proximity Read ↗

Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.Semantic proximity Read ↗

Genome-wide silencing screen in mesothelioma cells reveals that loss of function of BAP1 induces chemoresistance to ribonucleotide reductase inhibition: implication for therapySemantic proximity Read ↗

BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesotheliomaSemantic proximity Read ↗

An overview of BAP1 biological functions and current therapeutics.Semantic proximity Read ↗

BAP1 Loss Predicts Therapeutic Vulnerability in Malignant Peritoneal MesotheliomaSemantic proximity Read ↗

Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.